Can the Use of Oral Minocycline Improve Ischemic Stroke Outcomes?

2008 ◽  
Vol 21 (2) ◽  
pp. 159-164
Author(s):  
Kathy B. Lee
Keyword(s):  
United States ◽  
Ischemic Stroke ◽  
The United States ◽  
Sudden Onset ◽  
Pharmacological Agents ◽  
Stroke Outcomes ◽  
Stroke Treatment ◽  
The Brain ◽  
Brain Ischemic Stroke

Cerebrovascular accident (CVA), also known as ischemic stroke, is the sudden onset of neurologic deficit attributable to a focal vascular cause.1 It is the third leading cause of death, with the death rate being reported as 50.0 (per 100,000 population) in the United States in 2004.2 It is also a leading cause for serious, long-term disability in the United States. While there are various causes, the large majority of strokes result from either global or focal ischemia of the brain. Ischemic stroke accounts for 87% of all strokes, while intracerebral and subarachnoid hemorrhage makes up the remainder. 2 Currently, the primary pharmacological agents used in stroke treatment are thrombolytics, not without limitations, however, and antiplatelet therapy. 3 Minocycline, a semisynthetic tetracycline antibiotic, has recently gained attention as a neuroprotective agent. A recent study evaluated the use of minocycline in the treatment of acute stroke and demonstrated promising results.4 A review of the mechanisms of action and data presented in past studies will be examined to evaluate the efficacy and clinical impact of minocycline in the treatment of acute ischemic stroke.

scholarly journals Mesenchymal Stem Cell Derived Extracellular Vesicles for Repairing the Neurovascular Unit after Ischemic Stroke

Cells ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 767
Author(s):  
Courtney Davis ◽  
Sean I. Savitz ◽  
Nikunj Satani
Keyword(s):  
Ischemic Stroke ◽  
Extracellular Vesicles ◽  
Neurovascular Unit ◽  
Culture Conditions ◽  
Therapeutic Effects ◽  
Stroke Treatment ◽  
Inflammatory Molecules ◽  
The Brain

Ischemic stroke is a debilitating disease and one of the leading causes of long-term disability. During the early phase after ischemic stroke, the blood-brain barrier (BBB) exhibits increased permeability and disruption, leading to an influx of immune cells and inflammatory molecules that exacerbate the damage to the brain tissue. Mesenchymal stem cells have been investigated as a promising therapy to improve the recovery after ischemic stroke. The therapeutic effects imparted by MSCs are mostly paracrine. Recently, the role of extracellular vesicles released by these MSCs have been studied as possible carriers of information to the brain. This review focuses on the potential of MSC derived EVs to repair the components of the neurovascular unit (NVU) controlling the BBB, in order to promote overall recovery from stroke. Here, we review the techniques for increasing the effectiveness of MSC-based therapeutics, such as improved homing capabilities, bioengineering protein expression, modified culture conditions, and customizing the contents of EVs. Combining multiple techniques targeting NVU repair may provide the basis for improved future stroke treatment paradigms.

Abstract 187: Temporal Trends in Sex and Age Disparities in Acute Ischemic Stroke Treatment and Outcomes in the United States From 2004 to 2014

Stroke ◽  
2018 ◽  
Vol 49 (Suppl_1) ◽  
Author(s):  
Vasu Saini ◽  
Fadar O Otite ◽  
Priyank Khandelwal ◽  
Dileep R Yavagal ◽  
Seemant Chaturvedi ◽  
...  
Keyword(s):  
United States ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Temporal Trends ◽  
The United States ◽  
Stroke Treatment ◽  
Age Disparities

scholarly journals PCV25 MANAGEMENT OF ACUTE ISCHEMIC STROKE AND ITS LONG TERM EVOLUTION IN THE UNITED STATES AND CANADA

2011 ◽  
Vol 14 (3) ◽  
pp. A36
Author(s):  
A. Rouleau ◽  
V. Gobaux ◽  
C. Guilhaume ◽  
A. Yiou ◽  
D. Milea
Keyword(s):  
United States ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
The United States ◽  
Long Term Evolution ◽  
Term Evolution

EmboLess Mechanical Clot Removal Device: Possibility for Improving the Outcomes of Ischemic Stroke Patients

2010 ◽  
Author(s):  
Joseph Perosky ◽  
Adam Biddle ◽  
Kim DeGraaf ◽  
Whitney Hovan ◽  
Choi M. Li ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Treatment Options ◽  
The United States ◽  
Stroke Onset ◽  
Cerebral Vessel ◽  
Clot Removal ◽  
Mechanical Removal ◽  
The Brain

Ischemic stroke affects nearly 690,000 patients a year in the United States and is the leading cause of long-term disability and the third leading cause of death [1, 2]. Acute ischemic stroke occurs when a clot becomes lodged in a cerebral vessel, cutting off blood supply to areas of the brain. There are two treatment options for acute ischemic stroke: tissue plasminogen activator (beneficial within the first 4 hours of stroke onset), and mechanical removal (beneficial from 4 to 8 hours after stroke onset). The two FDA approved clot removal devices (MERCI and Penumbra) for ischemic stroke are capable of achieving revascularization rates between 48% and 80% [3, 4].

scholarly journals Temperature and Precipitation Associate With Ischemic Stroke Outcomes in the United States

2018 ◽  
Vol 7 (22) ◽  
Author(s):  
Stacy Y. Chu ◽  
Margueritte Cox ◽  
Gregg C. Fonarow ◽  
Eric E. Smith ◽  
Lee Schwamm ◽  
...  
Keyword(s):  
United States ◽  
Ischemic Stroke ◽  
The United States ◽  
Stroke Outcomes ◽  
Temperature And Precipitation

scholarly journals Transporter-Mediated Delivery of Small Molecule Drugs to the Brain: A Critical Mechanism That Can Advance Therapeutic Development for Ischemic Stroke

Pharmaceutics ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 154
Author(s):  
Erica I. Williams ◽  
Robert D. Betterton ◽  
Thomas P. Davis ◽  
Patrick T. Ronaldson
Keyword(s):  
Ischemic Stroke ◽  
Small Molecule ◽  
Current Knowledge ◽  
Organic Anion ◽  
The United States ◽  
Neurocognitive Deficits ◽  
Stroke Treatment ◽  
Small Molecule Drugs ◽  
Uptake Transporters ◽  
The Brain

Ischemic stroke is the 5th leading cause of death in the United States. Despite significant improvements in reperfusion therapies, stroke patients still suffer from debilitating neurocognitive deficits. This indicates an essential need to develop novel stroke treatment paradigms. Endogenous uptake transporters expressed at the blood-brain barrier (BBB) provide an excellent opportunity to advance stroke therapy via optimization of small molecule neuroprotective drug delivery to the brain. Examples of such uptake transporters include organic anion transporting polypeptides (OATPs in humans; Oatps in rodents) and organic cation transporters (OCTs in humans; Octs in rodents). Of particular note, small molecule drugs that have neuroprotective properties are known substrates for these transporters and include 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (i.e., statins) for OATPs/Oatps and 1-amino-3,5-dimethyladamantane (i.e., memantine) for OCTs/Octs. Here, we review current knowledge on specific BBB transporters that can be targeted for improvement of ischemic stroke treatment and provide state-of-the-art perspectives on the rationale for considering BBB transport properties during discovery/development of stroke therapeutics.

Stroke Epidemiology and Impact

2017 ◽  
Author(s):  
Virginia J Howard
Keyword(s):  
United States ◽  
Cause Of Death ◽  
Cerebrovascular Accident ◽  
Respiratory Diseases ◽  
Hemorrhagic Stroke ◽  
The United States ◽  
Common Type ◽  
Stroke Epidemiology ◽  
The Brain ◽  
Brain Ischemic Stroke

A cerebrovascular accident or stroke is an acute disease of blood vessels of the brain. Ischemic stroke is the most common type of stroke, estimated to be about 87% of all strokes. Ten percent are estimated to be intracerebral hemorrhagic stroke (ICH), and 3% subarachnoid hemorrhagic stroke (SAH). Stroke remains the fourth leading cause of death in the United States in 2012, only surpassed by diseases of the heart, cancer, and chronic lower respiratory diseases. Stroke is the 2nd leading cause of death worldwide. This chapter examines the epidemiology and impact of stroke in the United States and globally.

Contending Professions: Sciences of the Brain and Mind in the United States, 1850–2013

2015 ◽  
Vol 28 (1) ◽  
pp. 131-161 ◽  
Author(s):  
Andrew Scull
Keyword(s):  
Mental Health ◽  
United States ◽  
Health Care ◽  
The United States ◽  
Biological Psychiatry ◽  
Small Enterprise ◽  
Long Term Effects ◽  
Psychiatric Illnesses ◽  
The Brain

ArgumentThis paper examines the intersecting histories of psychiatry and psychology (particularly in its clinical guise) in the United States from the second half of the nineteenth century to the present. It suggests that there have been three major shifts in the ideological and intellectual orientation of the “psy complex.” The first period sees the dominance of the asylum in the provision of mental health care, with psychology, once it emerges in the early twentieth century, remaining a small enterprise largely operating outside the clinical arena, save for the development of psychometric technology. It is followed, between 1945 and 1980, by the rise of psychoanalytic psychiatry and the emergence of clinical psychology. Finally, the re-emergence of biological psychiatry is closely associated with two major developments: an emphasis that emerges in the late 1970s on rendering the diagnosis of psychiatric illnesses mechanical and predictable; and the long-term effects of the psychopharmacological revolution that began in the early 1950s. This third period has seen a shift the orientation of mainstream psychiatry away from psychotherapy, the end of traditional mental hospitals, and a transformed environment within which clinical psychologists ply their trade.

Computational Modeling of the Canine Middle Cerebral Artery During Localized Hypothermia Stroke Treatment

2013 ◽  
Author(s):  
Ryan A. Sikorski ◽  
Denise R. Merrill ◽  
Thomas L. Merrill
Keyword(s):  
United States ◽  
Blood Flow ◽  
Cell Death ◽  
Reperfusion Injury ◽  
Causes Of Death ◽  
Mechanical Thrombectomy ◽  
The United States ◽  
Ischemic Event ◽  
Stroke Treatment ◽  
The Brain

Stroke is caused by an interruption of brain blood supply and is one of the leading causes of death and disability in the United States. Each year 795,000 people experience a new stroke, of which 87% are ischemic [1]. The primary goal in stroke treatment is restoring blood flow in the effected regions of the brain, typically by using mechanical thrombectomy devices. However, after blood flow is restored, additional damage can occur in the form of reperfusion injury. Studies have shown that up to 50% of cell death from an ischemic event occurs as a result of reperfusion injury in cardiac patients [2].

scholarly journals Case report on ischemic stroke

2021 ◽  
pp. 56-57
Author(s):  
Chandini Kosuru ◽  
Sharmila T ◽  
Usha Sri Kanumula ◽  
Tanuja Lakshmi CH ◽  
Madhurismith V
Keyword(s):  
United States ◽  
Ischemic Stroke ◽  
Case Report ◽  
Clinical Features ◽  
Oxygen Supply ◽  
The United States ◽  
The Brain

This case report is mainly about the ISCHEMIC STROKE. In this the arteries become narrow, and fat get deposited (plaque) know as Atherosclerosis which is due to blockage of blood & oxygen supply to part of the brain. It affects more than 795,000 people in the United States.  Basing on clinical features, histopathological it has to diagnose and treated immediately to prevent the paralyzing life of people.

Sign in / Sign up

Export Citation Format

Share Document